GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemagen Diagnostics Inc (OTCPK:HMGN) » Definitions » Gross Margin %

Hemagen Diagnostics (Hemagen Diagnostics) Gross Margin % : 45.89% (As of Sep. 2012)


View and export this data going back to . Start your Free Trial

What is Hemagen Diagnostics Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Hemagen Diagnostics's Gross Profit for the three months ended in Sep. 2012 was $0.40 Mil. Hemagen Diagnostics's Revenue for the three months ended in Sep. 2012 was $0.88 Mil. Therefore, Hemagen Diagnostics's Gross Margin % for the quarter that ended in Sep. 2012 was 45.89%.


The historical rank and industry rank for Hemagen Diagnostics's Gross Margin % or its related term are showing as below:


HMGN's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.9
* Ranked among companies with meaningful Gross Margin % only.

Hemagen Diagnostics had a gross margin of 45.89% for the quarter that ended in Sep. 2012 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Hemagen Diagnostics was 0.00% per year.


Hemagen Diagnostics Gross Margin % Historical Data

The historical data trend for Hemagen Diagnostics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemagen Diagnostics Gross Margin % Chart

Hemagen Diagnostics Annual Data
Trend Sep03 Sep04 Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.48 38.24 45.13 38.14 39.91

Hemagen Diagnostics Quarterly Data
Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.84 36.77 31.59 47.78 45.89

Competitive Comparison of Hemagen Diagnostics's Gross Margin %

For the Biotechnology subindustry, Hemagen Diagnostics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hemagen Diagnostics's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemagen Diagnostics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Hemagen Diagnostics's Gross Margin % falls into.



Hemagen Diagnostics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Hemagen Diagnostics's Gross Margin for the fiscal year that ended in Sep. 2012 is calculated as

Gross Margin % (A: Sep. 2012 )=Gross Profit (A: Sep. 2012 ) / Revenue (A: Sep. 2012 )
=1.6 / 4.042
=(Revenue - Cost of Goods Sold) / Revenue
=(4.042 - 2.429) / 4.042
=39.91 %

Hemagen Diagnostics's Gross Margin for the quarter that ended in Sep. 2012 is calculated as


Gross Margin % (Q: Sep. 2012 )=Gross Profit (Q: Sep. 2012 ) / Revenue (Q: Sep. 2012 )
=0.4 / 0.876
=(Revenue - Cost of Goods Sold) / Revenue
=(0.876 - 0.474) / 0.876
=45.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Hemagen Diagnostics  (OTCPK:HMGN) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Hemagen Diagnostics had a gross margin of 45.89% for the quarter that ended in Sep. 2012 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Hemagen Diagnostics Gross Margin % Related Terms

Thank you for viewing the detailed overview of Hemagen Diagnostics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Hemagen Diagnostics (Hemagen Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
9033 Red Branch Road, Columbia, MD, USA, 21045
Hemagen Diagnostics Inc is a biotechnology company. It develops, manufactures and markets Food and Drug Administration cleared proprietary medical diagnostic test kits and components. The company's Virgo line of Immunoassays are used to aid in the diagnosis of autoimmune and infectious diseases and acute-phase proteins. The assays utilize multiple technologies including ELISA, immunofluorescence (IFA) and hemagglutination (HA). Its products include ANA Screen ELISA 96 Test System, Rubella IgG ELISA 96 Test System, AMA IFA 48 Test System and others.
Executives
Howard F Curd director

Hemagen Diagnostics (Hemagen Diagnostics) Headlines

No Headlines